mFOLFOX

DRUG11 trials

Sponsors

Peking University, Boehringer Ingelheim, Ali Shamseddine, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Arcus Biosciences, Inc.

Conditions

Adenocarcinoma of the StomachAdvanced Solid TumorsBiliary Tract CancerColorectal CancerColorectal NeoplasmsFirst Line TherapyGastric CancerGastroEsophageal Cancer

Phase 1

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

CompletedNCT03720678

Arcus Biosciences, Inc.Colorectal Cancer, GastroEsophageal Cancer

Start: 2018-11-18End: 2021-06-25Updated: 2024-05-24

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

CompletedNCT05116891

Cantargia ABAdvanced Solid Tumors, Biliary Tract Cancer, Colorectal Cancer +1

Start: 2021-09-22End: 2023-06-23Updated: 2023-07-03

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

RecruitingNCT05458219

Innovent Biologics (Suzhou) Co. Ltd.Locally Advanced Unresectable or Metastatic Solid Tumors

Start: 2022-10-26End: 2027-12-31Target: 470Updated: 2025-11-07

Phase 2

Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer

Peking UniversityGastric Cancer, Stomach Neoplasms

Start: 2008-01-31End: 2012-12-31Target: 263Updated: 2008-01-11

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

CompletedNCT00904839

Boehringer IngelheimColorectal Neoplasms

Start: 2009-05-31End: 2012-01-31Updated: 2015-02-04

Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

Active, not recruitingNCT03503630

Ali ShamseddineLocally Advanced Rectal Cancer

Start: 2018-07-20End: 2024-07-02Updated: 2024-01-31

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

CompletedNCT03647969

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestAdenocarcinoma of the Stomach, GastroEsophageal Cancer

Start: 2018-11-07End: 2024-07-19Updated: 2024-08-09

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

Active, not recruitingNCT04543695

Cancer Institute and Hospital, Chinese Academy of Medical SciencesRectal Cancer

Start: 2020-08-15End: 2025-06-01Target: 255Updated: 2024-03-26

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

RecruitingNCT05065957

InnoPharmax Inc.Biliary Tract Cancer

Start: 2022-03-29End: 2026-12-31Target: 180Updated: 2025-04-30

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

TerminatedNCT05998447

Genome & CompanyBiliary Tract Cancer

Start: 2023-09-18End: 2024-11-26Updated: 2025-12-16

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

RecruitingNCT07176312

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestFirst Line Therapy, Gastroesophageal Adenocarcinoma, HER2 + Gastric Cancer +2

Start: 2026-01-16End: 2029-03-01Target: 80Updated: 2026-02-04

Related Papers

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial

Nature Communications2026-02-27

CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.

2025-07-162 citations

Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.

Journal of Clinical Oncology2025-05-284 citations

Assessment of Immunoscore, MRI Tumor Regression Grade, and Neoadjuvant Rectal Score in Predicting Pathologic Response in Locally Advanced Rectal Cancer in the Averectal Study

Diagnostics2025-04-02

Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study.

Journal of Clinical Oncology2024-06-0113 citations

Abstract LB057: Pre-clinical characterization of IBI343, a site-specifically conjugated anti-Claundin18.2 ADC, for treating solid tumors

Cancer Research2024-04-052 citations

Results of a prospective phase II study of total neoadjuvant therapy for locally advanced rectal cancer.

Journal of Clinical Oncology2024-01-20

FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase 2 IKF-S628/AIO-STO-0417 (Moonlight) trial of the AIO.

Journal of Clinical Oncology2023-06-012 citations

Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Journal of Clinical Oncology2023-06-011 citations

Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial.

Journal of Clinical Oncology2023-06-01

Safety, efficacy and biomarker data in patients with non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab in combination with platinum doublet.

Journal of Clinical Oncology2023-06-01

Assessment of immunoscore and MRI tumor regression grade to predict complete pathologic response in patients with locally advanced rectal cancer: Data from phase II Averectal study.

Journal of Clinical Oncology2023-01-2414 citations

Quality-of-life outcomes after total neoadjuvant short course radiotherapy, chemo-immunotherapy, and total mesorectal excision for locally advanced rectal cancer.

Journal of Clinical Oncology2023-01-24

FOLFOX versus FOLFOX plus nivolumab and ipilimumab administered in parallel or sequentially versus FLOT plus nivolumab administered in parallel in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase 2 trial of the AIO.

Journal of Clinical Oncology2022-06-016 citations

High immunoscore as a predictor of outcome in patients who underwent chemoimmuno-therapy in locally advanced rectal cancer: A post-hoc analysis of the correlation between immunoscore and pCR in the Averectal study.

Journal of Clinical Oncology2022-01-192 citations

Abstract CT129: ARC-3: Updated results of etrumadenant (AB928) + modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients

Cancer Research2021-07-016 citations

338 Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + modified FOLFOX-6 (mFOLFOX-6)

Regular and Young Investigator Award Abstracts2020-11-01

Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.

2020-10-0757 citations

Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma

BMC Cancer2020-09-0121 citations

Abstract LB-387: Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3)

Cancer Research2020-08-151 citations

3 more papers not shown